Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis,

Status Completed

Clinical Trial Summary

Lymphatic Filariasis (LF), scabies and soil transmitted helminths (STH) are common neglected tropical diseases affecting the people of Fiji. There is a dedicated LF eradication program supported by the World Health Organization (WHO), however scabies and STH are currently managed on an individual level with symptomatic treatment as required. In an attempt to reduce the prevalence of LF globally, research is being undertaken into alternative, more effective treatment options. A recent study in Papua New Guinea demonstrated a new triple drug therapy (ivermectin, diethylcarbamazine and albendazole) is superior to the currently recommended two drug therapy (diethylcarbamazine and albendazole) used by WHO LF programs in the Pacific. However, adverse events were more frequent. Despite no serious adverse events being observed, it is necessary to conduct further studies to review the safety of this new triple therapy before it can be endorsed as an effective mass drug administration (MDA) regimen for LF in endemic countries. Fiji's burden of LF, that has been recalcitrant to previous MDA with diethylcarbamazine and albendazole, make it an ideal site to obtain further efficacy and safety data of the triple therapy. Ivermectin given to communities as MDA has been proven to be effective in reducing the community prevalence of scabies. What is not known is the effects of one dose versus two doses of ivermectin as MDA. This question will be reviewed within the design of the community randomized study. The prevalence of impetigo in a community is linked to scabies and this will also be reviewed. Ivermectin and albendazole are both effective individually against STH. The effectiveness of this combination of treatment as MDA in Fiji for STH has not been studied. The effectiveness for the individual in the short-term and the community in the longer-term will be reviewed. In addition, the acceptability and feasibility of the new therapy in communities at risk of these three diseases will be reviewed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03177993
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Completed
Phase	N/A
Start date	July 13, 2017
Completion date	October 24, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02572986` - A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies	Phase 3
Completed	`NCT00884728` - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory	N/A
Completed	`NCT05025696` - Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies	N/A
Completed	`NCT04205669` - Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon	Phase 4
Completed	`NCT02254564` - PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
Not yet recruiting	`NCT06404333` - Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)	Phase 2
Completed	`NCT03676140` - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )	Phase 3
Recruiting	`NCT05875441` - Efficacy and Safety Study of Moxidectin in Adults With Scabies	Phase 2
Completed	`NCT02978508` - Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.	Phase 3
Recruiting	`NCT04332068` - Ivermectin Safety in Small Children	Phase 2
Recruiting	`NCT04844905` - Adjunctive Ivermectin Mass Drug Administration for Malaria Control	Phase 3
Not yet recruiting	`NCT06380452` - Therapy for Scabies With Two Differently Concentrated Permethrin Creams	Phase 3
Completed	`NCT00604084` - Veron Scabies Education and Eradication Program	N/A
Completed	`NCT02485717` - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies	Phase 3
Completed	`NCT02485704` - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies	Phase 3
Recruiting	`NCT05310734` - PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies	Phase 4
Recruiting	`NCT04931680` - Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
Completed	`NCT06396507` - Sulfur vs. Different Regimes of Permethrin for Scabies	Phase 3
Completed	`NCT05862701` - Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies	Phase 1
Not yet recruiting	`NCT05500326` - Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji — FIT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms